Literature DB >> 22116693

Niacin: vitamin and antidyslipidemic drug.

Elaine L Jacobson1, H Kim, M Kim, M K Jacobson.   

Abstract

Niacin is defined collectively as nicotinamide and nicotinic acid, both of which fulfill the vitamin functions of niacin carried out by the bioactive forms NAD(P). In the last few decades numerous new enzymes that consume NAD(P) as substrates have been identified. The functions of these enzymes are emerging as exciting paradigm shifts, even though they are in early stages of discovery. The recent identification of the nicotinic acid receptor has allowed distinction of the drug-like roles of nicotinic acid from its vitamin functions, specifically in modulating blood lipid levels and undesirable side effects such as skin vasodilation and the more rare hepatic toxicities. This information has led to a new strategy for drug delivery for niacin, which, if successful, could have a major impact on human health through decreasing risk for cardiovascular disease. Understanding the many other effects of niacin has much broader potential for disease intervention and treatment in numerous diseases including cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22116693     DOI: 10.1007/978-94-007-2199-9_3

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  6 in total

1.  Triglyceride, nonesterified fatty acids, and prediabetic neuropathy: role for oxidative-nitrosative stress.

Authors:  Sergey Lupachyk; Pierre Watcho; Nailia Hasanova; Ulrich Julius; Irina G Obrosova
Journal:  Free Radic Biol Med       Date:  2012-02-04       Impact factor: 7.376

2.  Scalable syntheses of traceable ribosylated NAD+ precursors.

Authors:  M V Makarov; N W Harris; M Rodrigues; M E Migaud
Journal:  Org Biomol Chem       Date:  2019-09-20       Impact factor: 3.876

Review 3.  The chemistry of the vitamin B3 metabolome.

Authors:  Mikhail V Makarov; Samuel A J Trammell; Marie E Migaud
Journal:  Biochem Soc Trans       Date:  2018-12-17       Impact factor: 5.407

4.  Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B.

Authors:  Mattijs M Heemskerk; Sjoerd A A van den Berg; Amanda C M Pronk; Jan-Bert van Klinken; Mariëtte R Boon; Louis M Havekes; Patrick C N Rensen; Ko Willems van Dijk; Vanessa van Harmelen
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-01-28       Impact factor: 4.310

Review 5.  New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology.

Authors:  Anne Roulston; Gordon C Shore
Journal:  Mol Cell Oncol       Date:  2015-06-10

6.  A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers.

Authors:  Vincenzo Libri; Andrew P Brown; Giulio Gambarota; Jonathan Haddad; Gregory S Shields; Helen Dawes; David J Pinato; Ethan Hoffman; Peter J Elliot; George P Vlasuk; Eric Jacobson; Martin R Wilkins; Paul M Matthews
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.